Crizotinib in the treatment of ALK‑positive patients with advanced non‑small cell lung cancer

01/2019

MUDr. Jana Krejčí; MUDr. Daniel Krejčí; MUDr. Petr Opálka, CSc., MBA

Klinika pneumologie a hrudní chirurgie, Nemocnice Na Bulovce, Praha

SUMMARY

Lung cancer is one of the most common and most serious diseases. At present, we have different treatment approaches for non-small cell lung cancer not only according to histology but also on the basis of molecular genetic properties. Different treatment strategies exist according to molecularly defined markers in non-small-cell lung cancer. Molecular testing for at least epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) should be performed in all patients before therapy. Crizotinib is a tyrosine kinase inhibitor targeting ALK translocation. Based on Profile 1007 and Profile 1014 trial, it has become the basis of treatment for patients with ALK translocation. Our case report is a demonstration of the good performance of crizotinib in the second line of treatment of patients with lung adenocarcinoma.

KEY WORDS

non-small cell lung cancer, translocation ALK, crizotinib, ceritinib, alectinib